New Treatment Guidelines for Candidiasis – A Major Document to Study
![](https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2016/01/InExpertsWeTrust.jpg?resize=640%2C180&ssl=1)
In a much-quoted analysis, Lee found that most IDSA Guidelines were supported only by Level III quality data, the lowest category of evidence-based support[1]. The article concludes that more well-designed trials were needed, and clinical judgement should ultimately guide patient Continue reading New Treatment Guidelines for Candidiasis – A Major Document to Study